• In late July 2026, analysts at UBS projected that Colgate-Palmolive’s Q2 results would land broadly in line with consensus, underpinned by continued momentum in its international operations and core business segments.
• An interesting angle for investors is how this anticipated organic sales growth abroad aligns with Colgate-Palmolive’s long-term emphasis on emerging markets and product innovation.
• We’ll now examine how this international-driven earnings anticipation shapes Colgate-Palmolive’s broader investment narrative and its long-term growth assumptions.

Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

Colgate-Palmolive Investment Narrative Recap

To own Colgate-Palmolive, you need to believe in the resilience of its everyday brands and the compounding effect of disciplined international expansion. The UBS view that Q2 results should broadly match expectations reinforces the near term catalyst of steady, internationally driven organic growth, without materially changing the biggest current risk around cost pressures and consumer softness in key markets.

Against this backdrop, Colgate-Palmolive’s decision to lift its quarterly dividend to US$0.53 per share in March 2026 stands out. It signals ongoing confidence in cash generation at the same time the company is managing higher raw material costs and mixed demand in markets like North America, Brazil and India, which remain central to its growth story.

Yet, despite this consistency, investors should still pay close attention to the risk that prolonged consumer caution in key markets could...

Colgate-Palmolive's narrative projects $22.8 billion revenue and $3.5 billion earnings by 2029. This requires 3.8% yearly revenue growth and a $1.4 billion earnings increase from $2.1 billion today.

Uncover how Colgate-Palmolive's forecasts yield a $96.68 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$96.68 to US$125.13, showing how differently individual investors assess Colgate-Palmolive’s potential. When you weigh those opinions against the current focus on international organic growth as a key earnings driver, it becomes even more important to compare several viewpoints before forming a view on the company’s longer term performance.

Explore 3 other fair value estimates on Colgate-Palmolive - why the stock might be worth as much as 39% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Colgate-Palmolive research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Colgate-Palmolive research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Colgate-Palmolive's overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 38 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.